Thymmune Therapeutics
PrivateLast Round
Grant
Sep 29, 2023
Total Funding Raised
$52M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Thymmune Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Grant round in September 2023.
Thymmune Therapeutics is a biotechnology company developing a proprietary T-Lymune™ platform to restore and enhance the function of the thymus to address a wide range of immune-related disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, ML Platforms
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thymmune Therapeutics Comparables
Compare Thymmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tolerance Bio, Inc. | 86% | |
| TECregen | 78% | |
| Stratus Therapeutics | 75% |
For institutional investors. Book with your work email.
Thymmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 29, 2023 | ||||
| Seed | Mar 1, 2023 | ||||
| Grant | Feb 1, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Thymmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| Pags Group | Seed |
| Pillar VC | Seed |
| ARPA-H | Grant |
| NYBC Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 78% MoM.
- Jul 16, 2026
Open roles increased to 11, 39% of headcount.
For institutional investors. Book with your work email.
Thymmune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Thymmune Therapeutics's valuation, stock price, and market status.
Is Thymmune Therapeutics a public or private company?
Thymmune Therapeutics is a private company.
What is the current stock price of Thymmune Therapeutics?
Thymmune Therapeutics is a private company, so its shares have no public market price. Caplight tracks Thymmune Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Thymmune Therapeutics worth (valuation)?
Valuation information for Thymmune Therapeutics is not publicly available.
Can I buy Thymmune Therapeutics stock?
Thymmune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Thymmune Therapeutics's last funding round?
Thymmune Therapeutics's most recent funding round was Grant on September 29, 2023.
Who are the main investors in Thymmune Therapeutics?
Key investors in Thymmune Therapeutics include Pillar VC.
Will Thymmune Therapeutics IPO soon?
No public IPO plans have been announced for Thymmune Therapeutics.
How can I track Thymmune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Thymmune Therapeutics's shares on secondary markets.